Loading...

MedXY News - schizophrenia

MedXY AI/MedXY News/Tag: schizophrenia

MedXY News

EnglishTag

schizophrenia

25 all articles · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial immunotherapy heart failure obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology public health critical care artificial intelligence breast cancer Alzheimer's disease diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

LB-102 in Acute Schizophrenia: A Promising Benzamide Antipsychotic with Demonstrated Efficacy and Safety

LB-102 in Acute Schizophrenia: A Promising Benzamide Antipsychotic with Demonstrated Efficacy and Safety

The phase 2 NOVA1 trial demonstrates that LB-102 significantly improves acute schizophrenia symptoms with a favorable safety profile, supporting its potential as a novel treatment option.

Section: newsJul 18, 2026

Serial Dependence in Working Memory Distinguishes Schizophrenia From Bipolar Disorder With Psychosis

Serial Dependence in Working Memory Distinguishes Schizophrenia From Bipolar Disorder With Psychosis

A multisite case-control study found repulsive serial bias in schizophrenia, attractive bias in healthy controls, and mixed patterns in bipolar disorder, supporting serial dependence as a potential cognitive biomarker across the psychosis s

Section: newsJun 9, 2026

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed

A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.

Section: newsMay 29, 2026

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip

Section: Diabetes & EndocrinologyMay 26, 2026

Patient-Derived Neuronal Synapse Deficits Predict Brain Network Abnormalities and Cognitive Impairment in Schizophrenia

Patient-Derived Neuronal Synapse Deficits Predict Brain Network Abnormalities and Cognitive Impairment in Schizophrenia

A multimodal translational study links genetically driven synaptic deficits in patient-derived neurons to cortical structure, electrophysiology, and cognition in schizophrenia, supporting biologically informed stratification of cognitive im

Section: NeurologyMay 15, 2026

Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia

Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia

This landmark network meta-analysis of 438 RCTs evaluates 24 antipsychotics, revealing clozapine as the most effective while highlighting the novel muscarinic agonist xanomeline-trospium. The study emphasizes clinically relevant efficacy di

Section: newsMar 6, 2026

Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia

Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia

A landmark network meta- **Developing Article Components** I’m now diving deep into the content, focusing on fleshing out each section. The Highlight section’s first drafts are complete. I’m incorporating the study’s key findings on drug ef

Section: newsMar 6, 2026

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia

Section: Diabetes & EndocrinologyFeb 11, 2026

Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation

Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation

A comprehensive meta-analysis in JAMA Psychiatry reveals that current psychosocial interventions for schizophrenia and co-occurring substance use disorders offer negligible impact on symptoms and no significant effect on substance use reduc

Section: newsFeb 5, 2026

Glutamate Surges in Early Psychosis: Why Timing Matters for Targeted Therapeutics

Glutamate Surges in Early Psychosis: Why Timing Matters for Targeted Therapeutics

A cross-sectional study of never-medicated individuals reveals that elevated medial prefrontal cortex glutamate levels are specific to the first episode of psychosis and correlate with cognitive deficits, suggesting a critical window for gl

Section: newsJan 26, 2026

Processing Speed as a Core Endophenotype: New Evidence from a 115-Study Meta-Analysis in Schizophrenia

Processing Speed as a Core Endophenotype: New Evidence from a 115-Study Meta-Analysis in Schizophrenia

A comprehensive meta-analysis involving over 10,000 patients reveals that processing speed impairment is a profound and central deficit in schizophrenia, showing an effect size of -1.52 and playing a critical role in overall cognitive dysfu

Section: newsDec 24, 2025

Elevated Serotonin Release in Schizophrenia: New Insights Into Negative Symptom Pathophysiology

Elevated Serotonin Release in Schizophrenia: New Insights Into Negative Symptom Pathophysiology

A PET imaging study reveals increased frontal serotonin release in schizophrenia, particularly in deficit type, tied to worse negative symptoms.

Section: NeurologyDec 17, 2025

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological chall

Section: newsDec 1, 2025

Reduced Brain Iron Linked to Striatal Hyperdopaminergia in Schizophrenia: Insights from QSM MRI and PET Imaging

Reduced Brain Iron Linked to Striatal Hyperdopaminergia in Schizophrenia: Insights from QSM MRI and PET Imaging

This study reveals that lower brain iron levels in the substantia nigra-ventral tegmental area are associated with elevated striatal dopamine synthesis in schizophrenia, highlighting a potential new target for therapeutic intervention.

Section: NeurologyOct 30, 2025

Unveiling the Iron-Dopamine Link in Schizophrenia: Insights from QSM MRI and PET Imaging

Unveiling the Iron-Dopamine Link in Schizophrenia: Insights from QSM MRI and PET Imaging

This study reveals reduced brain iron in the substantia nigra-ventral tegmental area correlating with increased striatal dopamine synthesis in schizophrenia, suggesting novel neurobiological mechanisms and potential therapeutic targets.

Section: newsOct 30, 2025

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care

An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.

Section: newsOct 30, 2025

Comparative Efficacy and Tolerability of Seven Antipsychotics in Acute Schizophrenia: Insights from a Large Multicenter Randomized Trial

Comparative Efficacy and Tolerability of Seven Antipsychotics in Acute Schizophrenia: Insights from a Large Multicenter Randomized Trial

A multicenter randomized trial comparing seven antipsychotics in acute schizophrenia shows olanzapine and risperidone outperform several agents in efficacy but differ markedly in side effects, clarifying treatment choices.

Section: newsOct 29, 2025

Regional Specificity of Layer 3 Dendritic Spine Deficits in Schizophrenia: Implications for Cortical Circuit Dysfunction

Regional Specificity of Layer 3 Dendritic Spine Deficits in Schizophrenia: Implications for Cortical Circuit Dysfunction

This study reveals region- and size-specific dendritic spine deficits in cortical layer 3 neurons of schizophrenia patients, highlighting differential synaptic disruptions across visual and prefrontal cortical areas underpinning cognitive d

Section: NeurologyOct 27, 2025

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi

Section: Diabetes & EndocrinologyOct 22, 2025

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study

This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.

Section: Internal MedicineOct 19, 2025